Revolution Medicines (RVMD) Non-Current Deffered Revenue (2019 - 2022)

Revolution Medicines has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $5.4 million in Q3 2022.

• On a quarterly basis, Non-Current Deffered Revenue fell 44.02% year-over-year to $5.4 million in Q3 2022; TTM through Sep 2022 was $5.4 million, a 44.02% decrease from a year earlier, with the FY2021 full-year figure at $6.6 million, down 22.5% from the prior year.
• Non-Current Deffered Revenue was $5.4 million for Q3 2022 at Revolution Medicines, up from $3.8 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $14.7 million in Q4 2019, with the low at $3.8 million in Q2 2022.
• Average Non-Current Deffered Revenue over 4 years is $8.7 million, with a median of $8.3 million recorded in 2020.
• The sharpest annual moves came in 2021 and 2022: Non-Current Deffered Revenue dropped 0.97% in 2021, then tumbled 49.65% in 2022.
• Over 4 years, Non-Current Deffered Revenue stood at $14.7 million in 2019, then tumbled by 42.41% to $8.5 million in 2020, then decreased by 22.5% to $6.6 million in 2021, then decreased by 17.57% to $5.4 million in 2022.
• The last three Non-Current Deffered Revenue figures came in at $5.4 million (Q3 2022), $3.8 million (Q2 2022), and $5.7 million (Q1 2022), per Business Quant data.